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Abstract
Sleep is greatly affected by changes in metabolic state. A possible mechanism where energy-sensing and sleep-regulatory
functions overlap is related to lipid metabolism. Fatty acid synthase (FAS) plays a central role in lipid metabolism as a key
enzyme in the formation of long-chain fatty acids. We studied the effects of systemic administration of C75, an inhibitor of
FAS, on sleep, behavioral activity and metabolic parameters in mice. Since the effects of C75 on feeding and metabolism are
the opposite of ghrelin’s and C75 suppresses ghrelin production, we also tested the role of ghrelin signaling in the actions
of C75 by using ghrelin receptor knockout (KO) mice. After a transient increase in wakefulness, C75 elicited dose-dependent
and long lasting inhibition of REMS, motor activity and feeding. Simultaneously, C75 significantly attenuated slow-wave
activity of the electroencephalogram. Energy expenditure, body temperature and respiratory exchange ratio were
suppressed. The diurnal rhythm of feeding was completely abolished by C75. There was significant correlation between the
anorectic effects, the decrease in motor activity and the diminished energy expenditure after C75 injection. We found no
significant difference between wild-type and ghrelin receptor KO mice in their sleep and metabolic responses to C75. The
effects of C75 resemble to what was previously reported in association with visceral illness. Our findings suggest that sleep
and metabolic effects of C75 in mice are independent of the ghrelin system and may be due to its aversive actions in mice.
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Introduction
There is a known relationship among feeding, metabolism and
sleep. In mice and rats, metabolic states characterized by positive
energy balance are typically associated with increased sleep while
food deprivation stimulates wakefulness and motor activity. There
is a positive correlation between meal size and the length of the
subsequent sleep period in rats [1]. Increased feeding induced by
prior food deprivation elicits postprandial sleep [2–4]. Ventrome-
dial hypothalamic (VMH) lesion [5] is associated with increased
sleep time in rats. Increased adiposity induced by cafeteria diet or
[6] high-fat diet [7] and obesity due to leptin [8] or leptin receptor
[9] deficiency also leads to increases in sleep. Satiety and adiposity
signals are likely to mediate the effects of positive energy states on
sleep. Satiety hormones, such as cholecystokinin (CCK) [10–12]
and insulin [13,14] are released postprandially and stimulate sleep.
Hormones of the adipose tissue, such as leptin [15] and tumor
necrosis factor (TNF) [16,17], also enhance sleep and suppress
feeding. Postprandial sleep is prevented by CCK1 receptor
antagonists [3].
A possible focal point where the regulation of feeding and sleep
may converge is lipid metabolism. Fatty acid synthase (FAS) plays
a central role in lipid metabolism as a key enzyme in the formation
of long-chain fatty acids (reviewed in [18]). The role of FAS in
sleep regulation has not been studied. Since the activity of the
enzyme is enhanced in anabolic states, it is possible that
postprandial and obesity-associated enhanced sleep is related to
increased FAS activity. To gain insight into the potential role of
FAS in sleep regulation, we tested the effects of C75, an
irreversible FAS inhibitor [19–21], on sleep in mice.
Ghrelin has been shown to play a role in arousal responses to
fasting [22]. Ghrelin is a 28-amino acid peptide, produced by the
stomach and hypothalamic neurons (reviewed in [23]). It is the
endogenous ligand of the growth hormone secretagogue receptor
1a (GHSR 1a, ghrelin receptor; [24]). Ghrelin receptors are
expressed by various brain regions, such as the arcuate nucleus
(ARC), lateral hypothalamus (LH), VMH and suprachiasmatic
nucleus (SCN), structures known to be involved in feeding and
sleep regulation [25–27]. Ghrelin secretion is stimulated by fasting
and ghrelin enhances feeding and increases adiposity in rats
[28,29]. Growing body of evidence indicates that ghrelin signaling
plays a role in the function of arousal mechanisms. Systemic,
intracerebroventricular (icv) or intrahypothalamic administration
of ghrelin suppresses sleep [30–32] in rats. Ghrelin receptor KO
mice show attenuated arousal responses to food deprivation and to
the exposure of novel environment [22]. Ghrelin is also implicated
in the function of thermoregulatory mechanisms and in the
integration of sleep and thermoregulatory responses. Central
administration of ghrelin diminishes the activity of brown adipose
tissue, a key effector organ in non-shivering thermogenesis, by
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30651Figure 1. Wakefulness, non-rapid-eye-movement sleep (NREMS), rapid-eye-movement sleep (REMS), slow-wave activity of the
electroencephalogram (SWA), body temperature and locomotor activity in ghrelin receptor wild-type (WT) and knockout mice
(KO). Open symbols: vehicle injection, solid symbols: 7.5 mg/kg C75 intraperitoneally (ip). Data were calculated in 2-h time blocks. Time ‘‘0’’: time of
the injections. Activity is expressed as the percent of the total 24-h activity on the vehicle day. Dark shaded areas: dark period. Error bars: standard
error. Asterisks denote significant differences between control and treatment days (post hoc paired t-test).
doi:10.1371/journal.pone.0030651.g001
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product(s) of the preproghrelin gene play a role in coordinating
thermoregulatory/metabolic and sleep responses to metabolic
challenges. When fasted in the cold, normal mice develop
hypothermic (torpor) bouts and increased sleep during these
hypothermic periods. Ghrelin deficient preproghrelin knockout
(KO) mice are incapable of mounting sleep responses under these
conditions and enter precipitous, lethal, hypothermia [35].
FAS inhibitors, such as C75 greatly suppress ghrelin production
by the stomach and the hypothalamus [36]. C75 potently
suppresses eating [37] and energy expenditure [38,39]. Since
ghrelin stimulates feeding and transgenic mice with elevated
circulating ghrelin levels have increased energy expenditure [40],
it seemed possible that the inhibitory effects of C75 on feeding and
energy expenditure are mediated by its suppressive action on
ghrelin production. To test this hypothesis, we determined the
Figure 2. Wakefulness, NREMS, REMS, EEG SWA, body temperature and locomotor activity in ghrelin WT and KO mice after vehicle
injection (open symbols) and 15 mg/kg C75 (solid symbols) administration. See legends to Figure 1 for details.
doi:10.1371/journal.pone.0030651.g002
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ghrelin receptor deficient mice.
Methods
a. Animals
Male, 5–6 months old ghrelin receptor KO (originally named as
GHSR 2/2 mice, [41]) and wild-type (WT) mice were used in
the experiments. Breeding pairs of ghrelin receptor KO and WT
mice with a C57BL6J/129SvEv genetic background, backcrossed
to C57BL6J for 10 generations, were generated and given as a
generous gift by Drs. Roy G. Smith and Yuxiang Sun at Baylor
College of Medicine (Houston, TX), and further bred at
Washington State University. Each mouse used in the experiments
was genotyped (Transnetyx, Cordova, TN). Procedures were
carried out in accordance with the recommendations in the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. Protocol (ASAF # 3948) was approved by the
Figure 3. Wakefulness, NREMS, REMS, EEG SWA, body temperature and locomotor activity in ghrelin WT and KO mice after vehicle
injection (open symbols) and 30 mg/kg C75 (solid symbols) administration. See legends to Figure 1 for details.
doi:10.1371/journal.pone.0030651.g003
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State University.
b. Experiment 1: The effects of C75 on sleep-wake
activity, body temperature, home cage activity and food
intake
Surgery. Thebodyweightofthe WTand KOmiceatthetime
of surgery was 32.260.6 g and 32.860.7 g, respectively. During
surgery, mice were anesthetized with intraperitoneal (ip) injection of
ketamine-xylazine mixture (87 and 13 mg/kg, respectively), and all
efforts were made to minimize suffering. The animals were
implanted with cortical electroencephalographic (EEG) electrodes,
placed over the frontal and parietal cortices, and electromyographic
(EMG) electrodes in the dorsal neck muscles. The EEG and EMG
electrodes were connected to a pedestal, which was fixed to the skull
with dental cement. Temperature-sensitive transmitters were
implanted in the abdominal cavity for telemetry recordings. Mice
were allowed to recover from surgery for at least 2 weeks before
baseline recordings started. During the recovery and experimental
periods, all mice were housed in individual recording cages located
in a sound-attenuated environmental chamber at a constant
temperature (3061uC) and controlled light–dark cycles (12–12 h,
lightson:4am).Foodand waterwereavailableadlibitumthroughout
the experiments. The animals were fed with regular lab chow
(Harlan Teklad, Product No. 8460), in which fat, proteins, and
carbohydrates provided 17%, 29%, and 54% of calories,
respectively.
Sleep-wake recordings and analyses. Recording cables
connected the animals to commutators, which were further routed
to Grass Model15 Neurodata amplifier system (Grass Instrument
Division of Astro-Med, Inc., West Warwick, RI). The high-pass
and low-pass filters for EEG signals were 0.5 and 30.0 Hz,
respectively. The EMG signals were filtered with low and high cut-
off frequencies at 100 and 10,000 Hz, respectively. The outputs
from the amplifiers were fed into an analog-digital converter
(digitized at 256 Hz) and collected by computer (SleepWave
software, Biosoft Studio, Hersey, PA). Sleep-wake states were
scored visually off-line in 10-s segments according to the following
criteria. Non-rapid-eye-movement sleep (NREMS): high-voltage
EEG delta waves (0.5–4 Hz) and decreased muscle tone; rapid-
eye-movement sleep (REMS): predominant EEG theta activity (6–
8 Hz) and lack of muscle tone with occasional muscle twitches;
wakefulness (W): low-voltage EEG activity, and varying levels of
increased muscle activities. Time spent in W, NREMS and REMS
was calculated in 2- and 12-h blocks. EEG power data from each
artifact free 10-s segment were subjected to off-line spectral
analysis by fast Fourier transformation. EEG power data in the
range of 0.5 to 4.0 Hz during NREMS were used to compute
EEG slow-wave activity (SWA). EEG SWA data were normalized
for each animal by using the average EEG SWA across 24 h on
the baseline day as 100. The results were averaged in 2-h bins.
Table 1. The effects of C75 on sleep, wakefulness and slow-wave activity (SWA) of the electroencephalogram: statistical results.
7.5 mg/kg 15 mg/kg 30 mg/kg
df F p df F p df F p
NREMS
Treatm. 1,14 2.5 n.s. 1,18 1.5 n.s. 1,12 1.8 n.s.
Gen. 1,14 0.3 n.s. 1,18 2.1 n.s. 1,12 0.4 n.s.
Treatm.6Gen. 1,14 0.1 n.s. 1,18 0.7 n.s. 1,12 1.4 n.s.
Time6Gen. 11,154 0.8 n.s. 11,198 1.4 n.s. 11,132 1.4 n.s.
Treatm.6Time 11,154 3.2 P,0.05 11,198 4.3 P,0.05 11,132 7.6 P,0.05
REMS
Treatm. 1,14 13.9 P,0.05 1,18 14.6 P,0.05 1,12 86.9 P,0.05
Gen. 1,14 0.1 n.s. 1,18 1.5 n.s. 1,12 2.3 n.s.
Treatm.6Gen. 1,14 0.5 n.s. 1,18 0.9 n.s. 1,12 0.0 n.s.
Time6Gen. 11,154 2.9 P,0.05 11,198 1.1 n.s. 11,132 0.6 n.s.
Treatm.6Time 11,154 3.0 P,0.05 11,198 3.5 P,0.05 11,132 9.3 P,0.05
Wakefulness
Treatm. 1,14 4.2 n.s. 1,18 6.4 P,0.05 1,12 0.8 n.s.
Gen. 1,14 0.2 n.s. 1,18 1.9 n.s. 1,12 0.9 n.s.
Treatm.6Gen. 1,14 0.0 n.s. 1,18 1.6 n.s. 1,12 1.9 n.s.
Time6Gen. 11,154 1.0 n.s. 11,198 2.6 n.s. 11,132 1.2 n.s.
Treatm.6Time 11,154 3.2 P,0.05 11,198 3.4 P,0.05 11,132 6.6 P,0.05
SWA
Treatm. 1,14 1.2 n.s. 1,18 0.8 n.s. 1,11 10.1 P,0.05
Gen. 1,14 1.4 n.s. 1,18 1.7 n.s. 1,11 1.0 n.s.
Treatm.6Gen. 1,14 1.4 n.s. 1,18 1.7 n.s. 1,11 1.0 n.s.
Time6Gen. 11,154 3.0 P,0.05 11,198 1.6 n.s. 11,121 0.6 n.s.
Treatm.6Time 11,154 2.9 P,0.05 11,198 8.9 P,0.05 11,121 19.5 P,0.05
Treatm.: Treatment; Gen.: Genotype; NREMS: non-rapid-eye-movement sleep; REMS: rapid-eye-movement sleep; n.s.: not significant, df: degrees of freedom.
doi:10.1371/journal.pone.0030651.t001
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locomotor activity were recorded by Mini Mitter telemetry
system (Philips Respironics, Bend, OR). Temperature and
activity values were collected every 1 and 10 min, respectively,
throughout the experiment and were averaged into 2- and 12-h
time blocks. Activity values were normalized for each animal by
using the average activity across 24 h on the baseline day as 100.
Experimental procedures. After the recovery from
surgeries, the mice were connected to recording cables and were
given daily ip injections of saline for a 7-day habituation period.
On the first experimental day (baseline day), the animals were
injected with vehicle (ip, 1 ml/100 g body weight). On the
following day, C75 (Sigma-Aldrich, St. Louis, MO; dissolved in
RPMI 1640) was injected ip in the same volume. Three doses of
C75 were tested on separate groups of WT and ghrelin receptor
KO mice: 7.5 mg/kg (n=8 for both WT and KO), 15 mg/kg
(n=10 for both WT and KO) and 30 mg/kg (n=6 for WT and
n=8 for KO). The injections were performed during the last
15 min of the light phase. Recordings started from dark onset and
continued for 24 h. Due to the malfunction of one transmitter,
body temperature and activity data were collected only from 7 KO
mice in the 7.5 mg/kg group. Due to the occurrence of EEG
artifacts, one KO animal was excluded from the SWA analysis in
the 30 mg/kg group. Each day, the animals received pre-weighed
food pellets in their cage right after the injections. The leftovers
were collected and measured 24 h later and daily food intake was
calculated.
c. Experiment 2: The effects of C75 on oxygen uptake,
CO2 production, locomotor activity and food intake
In separate groups of mice (n=5 for WT and n=8 for ghrelin
KO), oxygen consumption (VO2, ml/kg/h) and carbon dioxide
production (VCO2, ml/kg/h) were measured with indirect
calorimetry (Oxymax System, Columbus Instruments, Columbus,
OH). Simultaneously, food intake (g/kg/h) and locomotor activity
were determined. Locomotor activity was measured by infrared
photocell sensors installed horizontally along the X- and Y-axes of
the calorimetry cage. The sensors provided 1.27 cm beam spacing,
16 infrared beams intersecting the chamber in the X- and 8 beams
in the Y-axis. The beam diameter was 0.32 cm. All four
measurements were taken every 10 min and the data were
collapsed into 1-h and 2-h bins. Respiratory exchange ratio (RER;
VCO2/VO2) was calculated. The animals were habituated to the
calorimetric cages for four days before the experiments. On the
fifth day, mice were injected with vehicle (ip, 1 ml/100 g) and on
the following day, they received 15 mg/kg C75, ip in the same
volume. The injections were performed during the last 15 min of
the light phase. Recordings started at light onset and continued for
24 h after each treatment. In 2 WT and 5 KO mice, food intake
was measured for one additional day.
d. Statistics
NREMS, REMS, W, SWA, average body temperature and
motor activity in Experiment 1 and VO2, RER, food intake and
activity in Experiment 2 were calculated in 2-h blocks. Three-way
mixed ANOVA was performed separately for each dose of C75
across 24 h (independent measure: genotype, repeated measures:
time and treatment). Daily food intake was analyzed by using two-
way mixed ANOVA (independent measure: genotype, repeated
measure: treatment) in Experiment 1. When ANOVA indicated
significant effects, post hoc paired t-tests (for repeated measures) or
Student’s t-tests (for independent measures) were performed for all
experiments. For Experiment 2, correlation between the effects of
C75 on feeding and activity, on feeding and VO2 and on activity
and VO2 was determined by using Pearson correlation test. For
this, differences between treatment day and baseline were
calculated in 1-h blocks and data were pooled from both
genotypes.
Results
Experiment 1. The effects of C75 on the sleep-wake
activity, body temperature, motor activity and food
intake in ghrelin receptor KO and WT mice
C75 elicited characteristic behavioral responses in both
genotypes. The animals became inactive after the injections and
tended to lie quietly on the cage floor. These responses were
particularly pronounced after the injection of the middle and the
high doses of C75. At the end of the 24-h recording period we
observed that the stool of C75-injected mice had been loose, often
fluid-state, diarrhea-like. Although this phenomenon was not
quantified, we did not notice any gross difference between the
stool of WT and ghrelin receptor KO animals.
The most striking effect of C75 on sleep-wake activity was the
dose-dependent, prolonged and robust suppression of REMS
Figure 4. Daily food intake after vehicle (white bars) and 7.5,
15 and 30 mg/kg C75 (black bars) injections in ghrelin receptor
WT and KO mice. Asterisks denote significant differences between
control and treatment days (paired t-test). All doses of C75 significantly
suppressed 24-h food intake. There was no significant difference in the
effect of C75 between the two genotypes.
doi:10.1371/journal.pone.0030651.g004
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REMS was 9.363.0, 17.069.3% and 76.569.7% below baseline
after the low, middle and high dose of C75, respectively. REMS
was completely eliminated for 6 h after the middle and for 12 h
after the highest dose of C75. Wakefulness was significantly
elevated in the first 2-h time period after the treatment and
subsequently, after a delay of ,12 h during the light phase.
Inverse changes in NREMS mirrored the wakefulness effects.
Similar sleep changes were observed in ghrelin receptor KO
animals. The daily amount of REMS was suppressed by 19.565.8,
24.766.1 and 66.869.6% after the injection of the three doses of
C75. The lack of significant genotype effects or genotype6treat-
ment interactions in ANOVA indicates that the sleep-wake
responses of ghrelin receptor KO animals were not different from
those of WTs (Table 1).
In WT mice, C75 treatment elicited dose-dependent significant
suppressions of the EEG SWA (Figures 1, 2 and 3). In response to
30 mg/kg C75, SWA remained 40–80% below baseline levels for
a period of 6 h. FAS inhibitor treatment elicited a robust and long-
lasting hypothermic response. In response to the highest dose of
C75, the hypothermia lasted for 10–12 h with the peak response of
a ,2.5uC drop in temperature. Body temperatures then gradually
returned to baseline by the beginning of the light period. The KO
animals showed very similar SWA and temperature responses; the
effects of C75 did not differ significantly in the two genotypes
(Table 1).
Activities of both WT and ghrelin receptor KO mice were
significantly reduced by C75 (Figures 1,2 and 3). These effects
were mainly confined to the first 12-h period when spontaneous
activity is the highest. In response to 30 mg/kg C75, activity was
suppressed by 69.368.6% in WT and 48.069.9% in KO animals
in the dark phase. C75 dose-dependently inhibited 24-h food
intake (Figure 4). WT mice ate 4.962.8% and KO mice
12.764.6% of the baseline food amounts following the highest
C75 dose. There were no significant differences in the motor
activity- or feeding-suppressing effects of C75 between the two
genotypes (Table 2).
Experiment 2. The effects of C75 on VO2, RER, feeding
and activity in ghrelin receptor KO and WT mice
In separate groups of KO and WT mice, we tested the effects of
15 mg/kg C75 on VO2, RER, feeding and activity. There were no
significant differences in VO2, RER, feeding and activity between
the two genotypes under normal, baseline conditions (Figure 5,
Table 3). Spontaneous feeding and motor activities showed typical
nocturnal pattern with 75–76% of feeding and 76–79% of total
daily activity taking place during the dark phase. Similar nocturnal
patterns were observed in VO2, with 61–62% of the daily oxygen
consumption occurring during the dark period. RER slightly
increased during the dark followed by a decline in the light period.
Consistent with our findings in Experiment 1, 15 mg/kg C75
significantly reduced motor activity and feeding during the dark
period in both WT and KO animals; there was no difference in
these effects between the two genotypes (Figure 5, Table 3).
During the light, i.e., 13–24 h after C75 treatment, feeding did not
differ significantly from baseline. In 2 WT and 5 KO mice, we
recorded feeding on the subsequent recovery day. Pooled data
from the 7 animals showed that feeding was still suppressed by
,30% below baseline during the dark phase of the recovery day,
i.e., 24–36 h after C75 injection (data not shown).
After C75 injection, VO2 was suppressed by 14.562.3% in
WTs and by 15.562.6% in KO mice during the night. The values
returned to baseline by the light period. RER was decreased
throughout the entire 24-h postinjection period. On the baseline
day, average 24-h RER values were 0.9160.01 and 0.8860.01 in
WT and KO mice, respectively, while after C75 treatment, these
values were suppressed to 0.7860.01 and 0.7660.01. The lack of
significant genotype effect or genotype6treatment interaction
indicates that the feeding, activity, VO2 and RER responses to
C75 were the same in both WT and KO mice (Table 3). Since
Table 2. The effects of C75 on body temperature, activity and feeding: statistical results.
7.5 mg/kg 15 mg/kg 30 mg/kg
df F p df F p df F p
Body Temperature
Treatm. 1,13 4.3 n.s. 1,18 0.3 n.s. 1,12 14.1 P,0.05
Gen. 1,13 0.1 n.s. 1,18 2.1 n.s. 1,12 0.8 n.s.
Treatm.6Gen. 1,13 0.0 n.s. 1,18 0.0 n.s. 1,12 0.1 n.s.
Time6Gen. 11,143 0.6 n.s. 11,198 0.9 n.s. 11,132 1.1 n.s.
Treatm.6Time 11,143 13.7 P,0.05 11,198 20.3 P,0.05 11,132 51.6 P,0.05
Activity
Treatm. 1,13 34.9 P,0.05 1,18 9.4 P,0.05 1,12 37.7 P,0.05
Gen. 1,13 0.7 n.s. 1,18 0.0 n.s. 1,12 1.3 n.s.
Treatm.6Gen. 1,13 0.7 n.s. 1,18 0.0 n.s. 1,12 1.3 n.s.
Time6Gen. 11,143 0.7 n.s. 11,198 0.5 n.s. 11,132 0.7 n.s.
Treatm.6Time 11,143 6.8 P,0.05 11,198 5.9 P,0.05 11,132 8.5 P,0.05
Feeding
Treatm. 1,14 84.9 P,0.05 1,18 81.2 P,0.05 1,12 120.8 P,0.05
Gen. 1,14 0.0 n.s. 1,18 0.3 n.s. 1,12 0.7 n.s.
Treatm.6Gen. 1,14 0.0 n.s. 1,18 0.7 n.s. 1,12 0.0 n.s.
doi:10.1371/journal.pone.0030651.t002
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the two genotypes, we pooled data from the two groups for
correlation analysis. We found significant correlation between the
effects of C75 on feeding and activity, the effects on feeding and
VO2 and the effects on activity and VO2 (Figure 6, Pearson
correlation test, p,0.001 for each).
Discussion
Our major finding is that systemic injection of C75 suppresses
motor activity, REMS, and SWA of the EEG in both normal and
ghrelin receptor KO mice. These behavioral and sleep effects are
accompanied by decreases in VO2, body temperature and RER.
We confirm our and others’ previous findings that spontaneous
sleep-wake activity [22], motor activity [22,42,43] and food intake
on standard laboratory diet [41,44] are not affected in ghrelin
receptor KO mice. Our results also confirm that C75 elicits robust
dose-dependent inhibition of 24-h food intake [37,39]. The effects
of C75 on the daily rhythm of feeding have not been reported
before. We show that C75 abolished the diurnal rhythm of
feeding. Night-time food intake was decreased to the level
normally seen during the day, the rest period in mice. The effects
Figure 5. Oxygen consumption (VO2), respirator exchange ratio (RER), food intake and motor activity after the ip injection vehicle
(open symbols) and 15 mg/kg C75 (solid symbols) in ghrelin receptor WT and KO mice. Data were calculated in 2-h time blocks. Activity is
expressed as absolute values. Dark shaded areas: dark period. Error bars: standard error. Asterisks denote significant differences between control and
treatment days (post hoc paired t-test).
doi:10.1371/journal.pone.0030651.g005
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two studies, no ‘‘gross changes’’ in the activity of mice [37] or no
‘‘obvious motoric effects’’ in rats [39] were observed after systemic
injection of C75. In the present study, we quantified the effects of
C75 on spontaneous motor activity in two separate sets of
experiments, by using two different methods. We found that
spontaneous motor activity was decreased after ip injection of C75
as measured both by the movement of implanted transponders
over a horizontal receiver in Experiment 1 and by the interruption
of infrared beams in Experiment 2.
The mechanism of the anorectic effects of C75 is not well
understood. It is possible that C75 stimulates satiety circuits and/
or suppresses orexigenic mechanisms or inhibits feeding by
eliciting visceral illness. In the present study, we tested the role
of orexinergic mechanisms in the effects of C75 by using ghrelin
receptor KO mice. Ghrelin plays a central role in physiologic
orexigenic mechanisms (reviewed in [23]) and stimulates motor
activity [31,45]. It has been postulated that increased behavioral
activity and feeding in the beginning of the dark period are due to
the activation of ghrelin circuits in the brain of nocturnal rodents
[31]. C75 is known to inhibit ghrelin secretion in mice [36] thus it
seemed possible that suppressed ghrelin secretion may account for
both the anorectic and motor activity-suppressing effects of C75.
In this case, intact ghrelin receptor-mediated signaling would be
Table 3. The effects of C75 on oxygen uptake (VO2),
respiratory exchange ratio (RER), feeding and activity:
statistical results.
df F p
VO2
Treatm. 1,11 26.7 P,0.05
Gen. 1,11 0.0 n.s.
Treatm.6Gen. 1,11 0.0 n.s.
Time6Gen. 11,121 0.4 n.s.
Treatm.6Time 11,121 12.4 P,0.05
RER
Treatm. 1,11 136.3 P,0.05
Gen. 1,11 2.8 n.s.
Treatm.6Gen. 1,11 0.2 n.s.
Time6Gen. 11,121 0.5 n.s.
Treatm.6Time 11,121 17.3 P,0.05
Feeding
Treatm. 1,11 114.3 P,0.05
Gen. 1,11 1.3 n.s.
Treatm.6Gen. 1,11 0.2 n.s.
Time6Gen. 11,121 1.3 n.s.
Treatm.6Time 11,121 18.0 P,0.05
Activity
Treatm. 1,11 24.4 P,0.05
Gen. 1,11 1.2 n.s.
Treatm.6Gen. 1,11 0.0 n.s.
Time6Gen. 11,121 0.5 n.s.
Treatm.6Time 11,121 9.5 P,0.05
doi:10.1371/journal.pone.0030651.t003
Figure 6. Correlation between the effects of 15 mg/kg C75 on
feeding and activity (upper panel), on feeding and VO2 (middle
panel) and on activity and VO2 (bottom panel). Pearson
correlation was calculated from the 1-h differences between C75 and
vehicle day. Data from both genotypes are pooled. Dashed lines: 95%
confidence intervals.
doi:10.1371/journal.pone.0030651.g006
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affect eating and activity in animals that lack ghrelin receptors.
The finding that C75-induced anorexia and motoric inhibition are
not attenuated in ghrelin receptor KO mice indicates that these
effects of C75 are unrelated to the function of ghrelin receptors.
We found significant correlation between the anorectic and
motor activity effects of C75. An overall decrease in motor activity
may, in theory, lead to decreased feeding. Although causality
cannot be determined with certainty in the present study, it seems
unlikely that the anorectic effects are exclusively due to the general
suppression of motor activity. First, while the overall time-courses
correlate significantly, there is a meaningful dissociation between
the motor activity- and feeding-suppressive effects of C75. For
example, in the ghrelin receptor KO mice, motor activity was
unchanged in the first 4 h after C75 treatment but feeding was
already suppressed to ,20% of the baseline. Second, if it is the
decreased motor activity that interferes with normal feeding
behavior after C75 injection then one would expect that the drive
for food, i.e., hunger, progressively increases during the dark.
Hunger induced by food restriction is accompanied by character-
istic changes in sleep-wake activity and c-Fos activation pattern in
the brain. Overnight food deprivation results in a ,24% increase
in waking time during the dark in mice [22]. This arousal response
was not observed after C75 injection supporting the notion that
the animals were not hungry, in spite of the fact that they ate less
than 18% of their normal food amount during the dark period.
Also, food deprivation stimulates c-Fos expression in orexigenic
brain structures such as the paraventricular nucleus (PVN), ARC
and LH, but systemic C75 treatment fails to elicit similar
activation pattern [46].
A possible explanation for the decreased feeding after C75
injection is that C75 elicits a satiety-like state. The sleep findings,
however, do not support this notion. Both naturally occurring
satiety that follows feeding [1–4] as well as injection of satiety-
inducing hormones such as cholecystokinin [11,12] lead to
increases in sleep. In our study, however, C75 induced dose-
dependent and long-lasting suppression of REMS. Thus the sleep
phenotype after C75 treatment does not match fasting or satiated
conditions but shows close similarity to the sleep pattern described
in visceral pain models. Visceral illness elicited by LiCl injections is
accompanied by transient increase in wakefulness followed by
long-lasting suppression of REMS [47,48]. An ip bolus injection of
LiCl causes significant increase in the latency and a significant
reduction in the occurrence of REM sleep in the immediate hours
following the injection. In contrast, NREM sleep occurrence is
only slightly affected by lithium administration. LiCl treatment
significantly reduces the relative delta power of the EEG after LiCl
treatment [49]. We also observed the suppression of EEG SWA,
i.e. delta waves, after C75 administration. Furthermore, LiCl
treatment leads to behavioral inactivity and causes rats to lie
quietly on the floor of the cage and elicits diarrhea [50]. These
sleep and behavioral effects are strikingly similar to those we found
in response to C75 treatment. We and others [51] also observed
soft, diarrhea-like stool of the animals after systemic injection of
C75. The pattern of brain c-Fos induction after C75 treatment is
also consistent with visceral illness. Systemic injection of 10 or
30 mg/kg C75 induces intensive c-Fos activation in the PVN and
the nucleus tractus solitarius/area postrema (NTS/AP) 1–2 h after
the injection [20,46]. Similarly, ip injection of malaise-inducing
doses of LiCl causes c-fos activation in the hypothalamic PVN and
in the brainstem NTS [52–54]. Systemic injection of C75
produces conditioned taste aversion further supporting the notion
of visceral illness [39,55].
In agreement with previous reports [44,56,57], there was no
difference in the baseline energy expenditure or RER between
ghrelin receptor KO and WT mice. Systemic bolus injection of
C75 suppressed energy expenditure as reported earlier [38,39] and
also decreased RER. There was no difference in these responses
between the two genotypes indicating that ghrelin signaling is not
required for the metabolic actions of C75. Suppressed energy
expenditure and RER are consistent with the state of energy
conservation and a shift to lipid catabolism, typical metabolic
responses to fasting. It is likely that these responses to C75 are also
secondary to suppressed feeding. The strong correlation between
the time course of the anorectic effect and the suppression of
energy expenditure further support this notion. In one study [37],
but not in others [46,58], C75 treated animals lost more weight
than the pair-fed controls leading to the speculation that C75 has
an additional, direct energy expenditure-stimulating effect [38].
The observation, however, that the treatment causes diarrhea
leads to an alternative explanation for the increased weight loss
after C75 administration.
C75 is a potent inhibitor of FAS in vitro. It has been proposed
that weight loss-inducing and food intake-suppressive effects of
C75 are related to the suppression of FAS activity in the
hypothalamus [37]. According to this hypothesis, FAS inhibi-
tion-induced increases in malonyl-CoA in hypothalamic neurons
provide a signal that leads to the activation of feeding-suppressive
mechanisms. The efficiency of systemic C75 treatment to suppress
brain FAS activity is, however, questionable. Systemic injection of
30 mg/kg C75 does not affect hypothalamic FAS enzyme activity
[20,59], therefore it can be ruled out that the observed sleep,
activity, body temperature and metabolic effects observed in our
experiments are related to the inhibition of FAS activity in the
brain. Furthermore, the plasma levels of C75 after administering
10 or 30 mg/kg ip reach less than 1% of the concentration needed
for FAS inhibition in vitro [20]. C75, however, has significant
anorectic, motor activity-inhibiting and metabolic effect in this
dose range suggesting that these actions are unrelated to the
inhibition of brain FAS. The most parsimonious explanation for
the observed actions is that they are due to the aversive actions of
C75. As a result of visceral illness, feeding and motor activity are
suppressed. Decreased eating and activity lead to suppressed
energy expenditure with the concomitant decrease in body
temperature and to the shift from carbohydrate to lipid utilization
manifested as decreased RER. The disrupted sleep pattern likely
reflects the aversive effects. Since C75 has sparked interest for its
potential use in body weight reduction and cancer therapy, its
effects on sleep, activity and metabolism need to be considered also
in this context. In conclusion, we demonstrated that systemic
injection of C75 induces long-lasting decreases in sleep, motor
activity, feeding, VO2 and RER. It is unlikely that these actions
are due to the effects of C75 on brain FAS or the ghrelin system.
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